Nixon, G, Moss, DM, Shone, A, Lalloo, D, Fisher, N, O'Neill, P, Ward, S and Biagini, G (2013) Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy, 68 (5). pp. 977-985. ISSN 0305-7453

[thumbnail of d_moss_2013.pdf]
d_moss_2013.pdf - Accepted Version
Available under License Creative Commons Attribution.

Download (335kB) | Preview


Atovaquone is used as a fixed-dose combination with proguanil (Malarone) for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travellers. Indeed, in the USA, between 2009 and 2011, Malarone prescriptions accounted for 70% of all antimalarial pre-travel prescriptions. In 2013 the patent for Malarone will expire, potentially resulting in a wave of low-cost generics. Furthermore, the malaria scientific community has a number of antimalarial quinolones with a related pharmacophore to atovaquone at various stages of pre-clinical development. With this in mind, it is timely here to review the current knowledge of atovaquone, with the purpose of aiding the decision making of clinicians and drug developers involved in the future use of atovaquone generics or atovaquone derivatives.

Item Type: Article
Uncontrolled Keywords: malaria, drug development, mechanism of action, resistance, drug interactions
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Depositing User: Symplectic
Date Deposited: 28 Feb 2017 10:40
Last Modified: 24 May 2019 14:26

Actions (login required)

View Item
View Item